Company Overview
Medasense develops AI-powered, non-invasive pain monitoring devices targeted at hospitals and post-operative care units. Headquartered in Lithuania, the company operates across the EU with an estimated €3.2 million revenue base, implying a sub-€10 million enterprise still in the early commercial phase. Its technology addresses a measurable clinical need—objective nociception monitoring—where most competitors remain US-centric.
Deal Context
The transaction is positioned as a strategic sale rather than a PE-led process. A larger medtech acquirer is reportedly seeking immediate EU regulatory access and proprietary AI pain-monitoring IP. Typical buyers would include mid-sized European or Israeli device groups lacking direct nociception capabilities, or US strategics expanding post-FDA clearance. The structure is most likely an outright acquisition rather than growth equity or acqui-hire.
Valuation Context
Baltic listed peers trade at 5.3–13.2x EV/EBITDA, with a median near 7.6x. Applying a 30–40 % private-company discount for scale, liquidity and single-product risk yields a realistic 5–8x EBITDA exit multiple. Assuming 20–25 % EBITDA margins (plausible for high-gross-margin device software), this implies an EV/revenue range of 1.0–2.0x. A strategic buyer could stretch to 2.5x revenue if the IP clears key EU accounts quickly, but the headline multiple will remain capped by the company’s limited installed base.
Triage Verdict
GO
- Fit: Healthtech M&A theme, EU regulatory moat and rumoured strategic intent align with mandate.
- Red flags: Sub-scale revenue and single-product concentration create binary outcome risk.
- Next step: Request management presentation and customer pipeline data under NDA to confirm margin trajectory and contract visibility.
Key Risk
EBITDA margins below 15 % would compress the exit multiple toward 4–5x, erasing most of the strategic premium.
Bottom line: Medasense offers a credible, low-double-digit EV/revenue entry for a strategic buyer if the IP and EU footprint are verified.
| # | Fund | AUM | YTD | Positions |
|---|---|---|---|---|
| 1 | Ma Investment Partnership, LP | $322.6B | +190.7% | 18 |
| 2 | Graticule Asia Macro Advisors LLC | $1.1T | +163.8% | 4 |
| 3 | Anther Capital Ltd | $3.8T | +162.3% | 31 |
| 4 | Central Asset Investments & Manag… | $261.4B | +146.6% | 63 |
| 5 | Oxbow Capital Management (HK) Ltd | $731.4B | +141.7% | 14 |
| 6 | Shengqi Capital (Hong Kong) Ltd | $95.6B | +141.4% | 10 |
| 7 | NVIDIA CORP | $31.5T | +123.8% | 12 |
| 8 | Elemental Capital Partners LLC | $422.8B | +115.7% | 18 |
| 9 | E20 Capital Ltd | $1.3T | +112.5% | 42 |
| 10 | Grand Alliance Asset Management Ltd | $302.6B | +111.7% | 24 |
| Security | Value | Weight |
|---|---|---|
| LUMENTUM HLDGS INC | $131.2B | 24.4% |
| AXT INC | $117.9B | 21.9% |
| TOWER SEMICONDUCTOR LTD | $107.7B | 20.0% |
| INTEL CORP | $99.4B | 18.5% |
| SANDISK CORP | $81.1B | 15.1% |
| Company | Ticker | Exchange | Expected | Deal Value |
|---|---|---|---|---|
| Cartesian Growth Corp IV | CGCFU | UNKNOWN | TBD | $287.5M |
| Research Alliance Corp IV | RACD | UNKNOWN | TBD | $75.0M |
| Gores Holdings XI, Inc. | GHXIU | UNKNOWN | TBD | $358.8M |
| Silentium Ltd. | SIAI | UNKNOWN | TBD | $19.8M |
| Pelican Acquisition II Corp | PLCIU | UNKNOWN | TBD | $86.2M |
| Company | Sector | Valuation |
|---|---|---|
| SpaceX | Space | $1.5T |
| Anthropic | Artificial Intelligence | $965.0B |
| OpenAI | Artificial Intelligence | $908.8B |